Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × pembrolizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 134 Melanoma 110 Breast Neoplasms 88 Squamous Cell Carcinoma of Head and Neck 82 Triple Negative Breast Neoplasms 73 Lung Neoplasms 58 Neoplasm Metastasis 46 Carcinoma, Renal Cell 40 Neoplasms 39 Head and Neck Neoplasms 37 Ovarian Neoplasms 35 Colorectal Neoplasms 35 Pancreatic Neoplasms 33 Carcinoma, Hepatocellular 31 Urinary Bladder Neoplasms 30 Recurrence 30 Carcinoma, Transitional Cell 30 Glioblastoma 29 Stomach Neoplasms 28 Brain Neoplasms 26 Sarcoma 23 Endometrial Neoplasms 22 Prostatic Neoplasms 21 Hodgkin Disease 19 Fallopian Tube Neoplasms 18 Carcinoma, Squamous Cell 18 Adenocarcinoma 17 Uterine Cervical Neoplasms 16 Multiple Myeloma 15 Lymphoma, Large B-Cell, Diffuse 15

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡